Decreased Trabecular Bone Score in Patients Affected by Fabry Disease

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2024 Oct 3

PMID 39361238

Authors

Emanuele Varaldo

Beatrice Giannone

Francesca Viglino

Fabio Settanni

Fabio Bioletto

Marco Barale

Massimo Procopio

Silvia Deaglio

Ezio Ghigo

Andrea Benso

Affiliations

Soon will be listed here.

Abstract

Background: Fabry disease (FD) is an inherited X-linked lysosomal storage disease characterized by increased risk of osteoporosis and fractures. The impact of FD on clinical measures of bone quality is unknown. This considered, aim of our study was to evaluate whether trabecular bone microarchitecture, measured by trabecular bone score (TBS), is altered in patients with FD compared to control subjects.

Methods: This retrospective monocentric study enrolled 14 patients (M/F 1/1, median age 46 [37-63] years, range 31-72 years) newly diagnosed with FD between January 2016 and July 2023 who underwent dual-energy X-ray absorptiometry (DXA) image at the time of diagnosis and 42 matched controls. In all subjects, data about bone mineral density (BMD) and lumbar spine TBS were collected and total calcium, parathyroid hormone (PTH), 25(OH) vitamin D, alkaline phosphatase (ALP), creatinine and estimated glomerular filtration rate (eGFR) were evaluated. In subjects with FD, globotriaosylsphingosine (lyso-Gb3), 24-hour proteinuria and albumin-creatinine ratio were also assessed.

Results: Patients with FD presented significantly lower lumbar spine TBS (1.29 [1.22-1.38] vs. 1.42 [1.39-1.47], p < 0.001) and lower lumbar spine BMD (0.916 ± 0.166 vs. 1.031 ± 0.125 g/cm, p = 0.008) compared to controls; moreover, FD was shown to be an independent risk factor for both low lumbar spine TBS (β = -0.118, p < 0.001) and BMD (β = -0.115, p = 0.009). No differences were found in serum calcium, ALP, 25(OH) vitamin D and eGFR in both groups, but FD patients had significantly higher PTH levels compared to controls (p = 0.016). Finally, 8 patients with FD presented either moderately or severely increased albuminuria and only 2 patients presented normal lyso-Gb3 levels.

Conclusion: Patients affected by FD present significantly lower lumbar spine TBS and BMD compared to controls. Our findings strongly support the importance of carrying out a thorough evaluation of bone status in all patients affected by FD at baseline.

Citing Articles

Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly.

Gasco V, Prencipe N, Cuboni D, Varaldo E, Sibilla M, Aversa L J Endocrinol Invest. 2024; .

PMID: 39739300 DOI: 10.1007/s40618-024-02519-8.

References

Germain D . Fabry disease. Orphanet J Rare Dis. 2010; 5:30. PMC: 3009617. DOI: 10.1186/1750-1172-5-30. View

Germain D, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M . Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019; 96(2):107-117. PMC: 6852597. DOI: 10.1111/cge.13546. View

Lin H, Chong K, Hsu J, Yu H, Shih C, Huang C . High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009; 2(5):450-6. DOI: 10.1161/CIRCGENETICS.109.862920. View

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

Hwu W, Chien Y, Lee N, Chiang S, Dobrovolny R, Huang A . Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009; 30(10):1397-405. PMC: 2769558. DOI: 10.1002/humu.21074. View

Monda E, Diana G, Graziani F, Rubino M, Bakalakos A, Linhart A . Impact of Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies. Circ Genom Precis Med. 2023; 16(6):e004252. DOI: 10.1161/CIRCGEN.123.004252. View

Germain D, Benistan K, Boutouyrie P, Mutschler C . Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet. 2005; 68(1):93-5. DOI: 10.1111/j.1399-0004.2005.00457.x. View

Mersebach H, Johansson J, Rasmussen A, Bengtsson B, Rosenberg K, Hasholt L . Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med. 2007; 9(12):812-8. DOI: 10.1097/gim.0b013e31815cb197. View

Talbot A, Ghali J, Nicholls K . Antiepileptic medications increase osteoporosis risk in male fabry patients: bone mineral density in an Australian cohort. JIMD Rep. 2014; 17:29-36. PMC: 4241203. DOI: 10.1007/8904_2014_328. View

Maione L, Tortora F, Modica R, Ramundo V, Riccio E, Daniele A . Pituitary function and morphology in Fabry disease. Endocrine. 2015; 50(2):483-8. DOI: 10.1007/s12020-015-0604-z. View

10.

Nose Y, Fujii H, Goto S, Kono K, Okamoto H, Watanabe K . Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease. Mol Genet Metab. 2023; 139(4):107634. DOI: 10.1016/j.ymgme.2023.107634. View

11.

Aitken T, Tiong M, Talbot A, Ruderman I, Nicholls K . The Effect of Fabry Disease Therapy on Bone Mineral Density. Diseases. 2024; 12(5). PMC: 11120203. DOI: 10.3390/diseases12050102. View

12.

Haseltine K, Chukir T, Smith P, Jacob J, Bilezikian J, Farooki A . Bone Mineral Density: Clinical Relevance and Quantitative Assessment. J Nucl Med. 2020; 62(4):446-454. PMC: 8049374. DOI: 10.2967/jnumed.120.256180. View

13.

Kanis J . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994; 4(6):368-81. DOI: 10.1007/BF01622200. View

13.

Zar-Kessler C, Karaa A, Sims K, Clarke V, Kuo B . Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Therap Adv Gastroenterol. 2016; 9(4):626-34. PMC: 4913334. DOI: 10.1177/1756283X16642936. View

14.

Bousson V, Bergot C, Sutter B, Levitz P, Cortet B . Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporos Int. 2011; 23(5):1489-501. DOI: 10.1007/s00198-011-1824-6. View

15.

Ulivieri F, Silva B, Sardanelli F, Hans D, Bilezikian J, Caudarella R . Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014; 47(2):435-48. DOI: 10.1007/s12020-014-0280-4. View

16.

Faggiano A, Pisani A, Milone F, Gaccione M, Filippella M, Santoro A . Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab. 2006; 91(11):4319-25. DOI: 10.1210/jc.2006-0858. View

16.

Vinolas H, Grouthier V, Mehsen-Cetre N, Boisson A, Winzenrieth R, Schaeverbeke T . Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score. Clin Endocrinol (Oxf). 2018; 89(2):148-154. DOI: 10.1111/cen.13743. View

17.

Strotmeyer E, Cauley J, Schwartz A, Nevitt M, Resnick H, Bauer D . Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005; 165(14):1612-7. DOI: 10.1001/archinte.165.14.1612. View